Publicatie
Publication date
Estimation of the number of RSV-associated hospitalisations in adults in the European Union.
Osei-Yeboah, R., Spreeuwenberg, P., Del Riccio, M., Fischer, T.K., Egeskov-Cavling, A.M., Bøås, H., Boven, M. van, Wang, X., Lehtonen, T., Bangert, M., Campbell, H., Paget, J. Estimation of the number of RSV-associated hospitalisations in adults in the European Union. Journal of Infectious Diseases: 2023, 228(11), p. 1539-1548.
Read online
Background
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in adults that can result in hospitalisations. Estimating RSV-associated hospitalisation is critical for planning RSV-related healthcare across Europe.
Methods
We gathered RSV-associated hospitalisation estimates from the RSV Consortium in Europe (RESCEU) for adults in Denmark, England, Finland, Norway, Netherlands, and Scotland from 2006-2017. We extrapolated these estimates to 28 EU countries using nearest-neighbour matching, multiple imputations, and two sets of 10 indicators.
Results
On average, 158229 (95%CI:140865-175592) RSV-associated hospitalisations occur annually among adults in the EU (≥18years); 92% of these hospitalisations occur in adults ≥65years. Among 75-84years, the annual average is estimated at 74519 (69923-79115) at a rate of 2.24 (2.10-2.38) per 1000. Among ≥85years, the annual average is estimated at 37904 (32444-43363) at a rate of 2.99 (2.56-3.42).
Conclusion
Our estimates of RSV-associated hospitalisations in adults are the first analysis integrating available data to provide the disease burden across the EU. Importantly, for a condition considered in the past to be primarily a disease of young children, the average annual hospitalisation estimate in adults was lower but of a similar magnitude to the estimate in young children(0-4years): 158229 (140865-175592) versus 245244 (224688-265799).
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in adults that can result in hospitalisations. Estimating RSV-associated hospitalisation is critical for planning RSV-related healthcare across Europe.
Methods
We gathered RSV-associated hospitalisation estimates from the RSV Consortium in Europe (RESCEU) for adults in Denmark, England, Finland, Norway, Netherlands, and Scotland from 2006-2017. We extrapolated these estimates to 28 EU countries using nearest-neighbour matching, multiple imputations, and two sets of 10 indicators.
Results
On average, 158229 (95%CI:140865-175592) RSV-associated hospitalisations occur annually among adults in the EU (≥18years); 92% of these hospitalisations occur in adults ≥65years. Among 75-84years, the annual average is estimated at 74519 (69923-79115) at a rate of 2.24 (2.10-2.38) per 1000. Among ≥85years, the annual average is estimated at 37904 (32444-43363) at a rate of 2.99 (2.56-3.42).
Conclusion
Our estimates of RSV-associated hospitalisations in adults are the first analysis integrating available data to provide the disease burden across the EU. Importantly, for a condition considered in the past to be primarily a disease of young children, the average annual hospitalisation estimate in adults was lower but of a similar magnitude to the estimate in young children(0-4years): 158229 (140865-175592) versus 245244 (224688-265799).
Background
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in adults that can result in hospitalisations. Estimating RSV-associated hospitalisation is critical for planning RSV-related healthcare across Europe.
Methods
We gathered RSV-associated hospitalisation estimates from the RSV Consortium in Europe (RESCEU) for adults in Denmark, England, Finland, Norway, Netherlands, and Scotland from 2006-2017. We extrapolated these estimates to 28 EU countries using nearest-neighbour matching, multiple imputations, and two sets of 10 indicators.
Results
On average, 158229 (95%CI:140865-175592) RSV-associated hospitalisations occur annually among adults in the EU (≥18years); 92% of these hospitalisations occur in adults ≥65years. Among 75-84years, the annual average is estimated at 74519 (69923-79115) at a rate of 2.24 (2.10-2.38) per 1000. Among ≥85years, the annual average is estimated at 37904 (32444-43363) at a rate of 2.99 (2.56-3.42).
Conclusion
Our estimates of RSV-associated hospitalisations in adults are the first analysis integrating available data to provide the disease burden across the EU. Importantly, for a condition considered in the past to be primarily a disease of young children, the average annual hospitalisation estimate in adults was lower but of a similar magnitude to the estimate in young children(0-4years): 158229 (140865-175592) versus 245244 (224688-265799).
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in adults that can result in hospitalisations. Estimating RSV-associated hospitalisation is critical for planning RSV-related healthcare across Europe.
Methods
We gathered RSV-associated hospitalisation estimates from the RSV Consortium in Europe (RESCEU) for adults in Denmark, England, Finland, Norway, Netherlands, and Scotland from 2006-2017. We extrapolated these estimates to 28 EU countries using nearest-neighbour matching, multiple imputations, and two sets of 10 indicators.
Results
On average, 158229 (95%CI:140865-175592) RSV-associated hospitalisations occur annually among adults in the EU (≥18years); 92% of these hospitalisations occur in adults ≥65years. Among 75-84years, the annual average is estimated at 74519 (69923-79115) at a rate of 2.24 (2.10-2.38) per 1000. Among ≥85years, the annual average is estimated at 37904 (32444-43363) at a rate of 2.99 (2.56-3.42).
Conclusion
Our estimates of RSV-associated hospitalisations in adults are the first analysis integrating available data to provide the disease burden across the EU. Importantly, for a condition considered in the past to be primarily a disease of young children, the average annual hospitalisation estimate in adults was lower but of a similar magnitude to the estimate in young children(0-4years): 158229 (140865-175592) versus 245244 (224688-265799).